Ionis Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IONS and other ETFs, options, and stocks.

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. 

CEO
Brett P. Monia
CEOBrett P. Monia
Employees
1,402
Employees1,402
Headquarters
Carlsbad, California
HeadquartersCarlsbad, California
Founded
1989
Founded1989
Employees
1,402
Employees1,402

IONS Key Statistics

Market cap
9.60B
Market cap9.60B
Price-Earnings ratio
-26.90
Price-Earnings ratio-26.90
Dividend yield
Dividend yield
Average volume
4.07M
Average volume4.07M
High today
$57.36
High today$57.36
Low today
$56.10
Low today$56.10
Open price
$56.32
Open price$56.32
Volume
2.71M
Volume2.71M
52 Week high
$86.74
52 Week high$86.74
52 Week low
$40.03
52 Week low$40.03

Stock Snapshot

With a market cap of 9.6B, Ionis Pharmaceuticals(IONS) trades at $56.55. The stock has a price-to-earnings ratio of -26.90.

On 2026-07-25, Ionis Pharmaceuticals(IONS) stock moved within a range of $56.10 to $57.36. With shares now at $56.55, the stock is trading +0.8% above its intraday low and -1.4% below the session's peak.

Trading volume for Ionis Pharmaceuticals(IONS) stock has reached 2.71M, versus its average volume of 4.07M.

Over the past 52 weeks, Ionis Pharmaceuticals(IONS) stock has traded between a high of $86.74 and a low of $40.03.

Over the past 52 weeks, Ionis Pharmaceuticals(IONS) stock has traded between a high of $86.74 and a low of $40.03.

IONS News

TipRanks 2d
Ionis Stock Pops as Analysts Tout Drug Edge - TipRanks

...

Ionis Stock Pops as Analysts Tout Drug Edge - TipRanks
Simply Wall St 2d
US High Growth Tech Stocks to Watch for Potential Expansion

Over the last 7 days, the United States market has dropped 1.4%, but it remains up by 16% over the past year, with earnings expected to grow by 18% per annum in...

US High Growth Tech Stocks to Watch for Potential Expansion
Seeking Alpha 3d
Ionis drops as Arrowhead posts late-stage trial win for lipid-lowering drug

Arrowhead Pharmaceuticals (ARWR) on Wednesday announced a late-stage trial win for its lipid-lowering agent plozasiran in patients with severe hypertriglyceride...

Ionis drops as Arrowhead posts late-stage trial win for lipid-lowering drug

Analyst ratings

88%

of 24 ratings
Buy
87.5%
Hold
12.5%
Sell
0%

More IONS News

TipRanks 4d
Ionis Pharmaceuticals price target lowered to $89 from $106 at Guggenheim

Guggenheim lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $89 from $106 and keeps a Buy rating on the shares. The firm is revising some of i...

Nasdaq 7d
Cathie Wood Just Bet Big on This Biotech Stock

Key Points The biotech has a strong pipeline and is growing its revenue. In June, the FDA approved Ionis's drug, Tryngolza, to treat severe hypertriglyceridem...

Cathie Wood Just Bet Big on This Biotech Stock

People also own

Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.